NASDAQ:THMA Thimble Point Acquisition (THMA) Stock Price, News & Analysis → Americans Now Need $1.46M to Retire… (From Crypto 101 Media) (Ad) Free THMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$4.31▼$10.0052-Week Range N/AVolumeN/AAverage Volume154,984 shsMarket Capitalization$2,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Thimble Point Acquisition alerts: Email Address Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. About Thimble Point AcquisitionThimble Point Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New Haven, Connecticut.Read More Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. THMA Stock News HeadlinesFebruary 1, 2024 | sports.yahoo.comNBA Odds, Betting Lines & Point Spreads - Yahoo SportsSeptember 23, 2023 | seekingalpha.comIPXX.UN Inflection Point Acquisition Corp. II UnitsAugust 3, 2023 | usnews.comPoint Loma Nazarene UniversityJanuary 17, 2023 | finance.yahoo.comLink Enters Singapore through the Acquisition of Jurong Point and Swing By @ Thomson PlazaJuly 7, 2022 | thestreet.comThimble Point Acquisition Corp. Class A NewsDecember 20, 2021 | reuters.comPear Therapeutics IncDecember 8, 2021 | finance.yahoo.comPear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue GuidanceDecember 8, 2021 | finance.yahoo.comPear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use DisorderDecember 8, 2021 | finance.yahoo.comPear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx ConferenceDecember 8, 2021 | finance.yahoo.comPear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics CompanyDecember 8, 2021 | finance.yahoo.comPear Therapeutics Stock Rises on First Day of TradingAugust 2, 2021 | prnewswire.comSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Thimble Point Acquisition Corp. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSee More Headlines Receive THMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Thimble Point Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health Services Sub-IndustryN/A Current SymbolNASDAQ:THMA CUSIPN/A CIK1835567 WebN/A Phone203-680-8543FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.12) per share Price / BookN/AMiscellaneous Outstanding Shares8,211,000Free FloatN/AMarket Cap$2,000.00 OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key CompetitorsOncoSec MedicalNASDAQ:ONCSQViveve MedicalNASDAQ:VIVEKaleido BiosciencesNASDAQ:KLDOGenocea BiosciencesNASDAQ:GNCAHTG Molecular DiagnosticsNASDAQ:HTGMQView All Competitors This page (NASDAQ:THMA) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & CompanyBiden Nomination CANCELED?The Freeport SocietyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media348 million Americans lives to END as we know it?The Oxford ClubA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Thimble Point Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
